These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31450855)

  • 1. Procurement of Category 2 Vaccines in China.
    Zhuang JL; Wagner AL; Laffoon M; Lu YH; Jiang QW
    Vaccines (Basel); 2019 Aug; 7(3):. PubMed ID: 31450855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine Prices: A Systematic Review of Literature.
    Hussain R; Bukhari NI; Ur Rehman A; Hassali MA; Babar ZU
    Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33137948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.
    Kane MA; Hadler SC; Lee L; Shapiro CN; Cui F; Wang X; Kumar R
    Vaccine; 2013 Dec; 31 Suppl 9():J15-20. PubMed ID: 24331015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The landscape of vaccines in China: history, classification, supply, and price.
    Zheng Y; Rodewald L; Yang J; Qin Y; Pang M; Feng L; Yu H
    BMC Infect Dis; 2018 Oct; 18(1):502. PubMed ID: 30286735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine vial monitor availability and use in low- and middle-income countries: A systematic review.
    Eriksson P; Gessner BD; Jaillard P; Morgan C; Le Gargasson JB
    Vaccine; 2017 Apr; 35(17):2155-2161. PubMed ID: 28364924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between provincial income levels and drug prices in China over the period 2010-2017.
    Shi W; Wouters OJ; Liu G; Mossialos E; Yang X
    Soc Sci Med; 2020 Oct; 263():113247. PubMed ID: 32799026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mixed integer programming model for vaccine pricing within a group purchasing organization.
    Yu Z; Keskinocak P; Orenstein WA; Toktay LB
    Vaccine; 2024 Mar; 42(8):1892-1898. PubMed ID: 37977944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Children's Vaccine Initiative and vaccine supply: the role of the public sector.
    van Noort RB
    Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine bidding, procurement and distribution management practices in mainland China: A nationwide study.
    Wang W; Wang Y; Wang Y; Yan F; Wang N; Fu C
    Vaccine; 2021 Dec; 39(52):7584-7589. PubMed ID: 34802784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market.
    Malhame M; Baker E; Gandhi G; Jones A; Kalpaxis P; Iqbal R; Momeni Y; Nguyen A
    Vaccine X; 2019 Aug; 2():100033. PubMed ID: 31384748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of New Vaccine Introduction - Worldwide, September 2016.
    Loharikar A; Dumolard L; Chu S; Hyde T; Goodman T; Mantel C
    MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1136-1140. PubMed ID: 27764083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EPI Revolving Fund: quality vaccines at low cost.
    EPI Newsl; 1997 Aug; 19(4):6-7. PubMed ID: 12348218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-GAVI sustainability of the Haemophilus influenzae type b vaccine program: The potential role of economic evaluation.
    Le P; Nghiem VT; Swint JM
    Hum Vaccin Immunother; 2016 Sep; 12(9):2403-5. PubMed ID: 27135964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
    Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
    Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines.
    De la Hoz-Restrepo F; Castañeda-Orjuela C; Paternina A; Alvis-Guzman N
    Vaccine; 2013 Jul; 31 Suppl 3():C80-7. PubMed ID: 23777697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The introduction of new vaccines into developing countries II. Vaccine financing.
    Mahoney RT; Ramachandran S; Xu Z
    Vaccine; 2000 Jun; 18(24):2625-35. PubMed ID: 10781848
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.